GBT
CRSP icon

Grove Bank & Trust’s CRISPR Therapeutics CRSP Stock Holding History

Grove Bank & Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-79
Closed -$3.59K – 614
2023
Q3 		$3.59K Buy
+79
New +$4.08K ﹤0.01% 602

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Grove Bank & Trust's CRSP Position: Q4 2023 in Review

Grove Bank & Trust sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 79 shares — an estimated $3.59K sold.

Grove Bank & Trust first reported a position in CRSP in Q3 2023 and held it in 1 quarter. The position peaked at $3.59K in Q3 2023. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

  • Grove Bank & Trust reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Grove Bank & Trust sold 79 CRISPR Therapeutics shares in Q4 2023, an estimated $3.59K.
  • Grove Bank & Trust first reported a position in CRISPR Therapeutics in Q3 2023 and held it in 1 quarter.
  • Grove Bank & Trust's CRISPR Therapeutics position peaked at $3.59K in Q3 2023.
  • 472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.